Evaluation and Treatment of Patients With Dermatologic Diseases

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00001506
First received: November 3, 1999
Last updated: June 17, 2014
Last verified: February 2014

November 3, 1999
June 17, 2014
June 1996
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00001506 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluation and Treatment of Patients With Dermatologic Diseases
Evaluation and Treatment of Subjects With Dermatologic Diseases

This is a training, natural history of disease, and screening protocol for the evaluation, treatment and follow-up of patients with dermatologic diseases and systemic diseases with cutaneous manifestations. Patients enrolled in this protocol will be evaluated and treated according to generally available, standard procedures and therapeutic modalities. Samples of blood and skin will be studied by routine and specialized investigative methods to establish these patients' diagnosis, response to treatment, and/or disease progression.

Background

This is a training, natural history of disease, and screening protocol for the evaluation, treatment and follow-up of patients with dermatologic diseases and systemic diseases with cutaneous manifestations. This protocol was developed to allow subject enrollment for teaching purposes and to allow for second opinions regarding relatively complicated patients. The latter function promotes a critical link between the NCI, CCR Dermatology Branch and the local and national extramural medical communities.

Objective

Primary:

- To provide clinical material to fulfill the educational mission of the

Dermatology Branch.

- To learn about the natural history of selected dermatologic diseases.

Secondary:

  • To screen patients for inclusion in other protocols.
  • To assist in the diagnosis and/or management of patients with rare skin diseases and congenital or genetically linked skin conditions.

Eligibility

All subjects regardless of age, gender, or racial/ethnic group with dermatologic disease or systemic disease with cutaneous manifestations.

Design

Patients enrolled in this protocol will be evaluated and treated according to generally available, standard procedures and therapeutic modalities. Samples of blood and skin will be studied by routine and specialized investigative methods to establish these patients diagnosis, response to treatment, and/or disease progression.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
  • Connective Tissue Disease
  • Skin Disease
Not Provided
Not Provided
Murray JC, Pollack SV, Pinnell SR. Keloids: a review. J Am Acad Dermatol. 1981 Apr;4(4):461-70. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
500
Not Provided
Not Provided
  • INCLUSION CRITERIA:

Patients of any age, of both genders, and all racial/ethnic groups with dermatologic diseases or systemic diseases with cutaneous manifestations.

Women of childbearing potential, or who are pregnant or lactating, will only undergo tests and procedures, and/or receive medications for which data exists proving minimal risk to the fetus and/or child. Only tests that are clinically indicated for diagnosis will be performed.

Patients must be referred by a physician.

EXCLUSION CRITERIA:

Patients with cognitive impairment.

Pregnancy or lactation, if this status precludes proposed diagnostic procedures or therapies because of known untoward effects on mother and/or child.

Both
Not Provided
No
Contact: Sharon Osgood, R.N. (301) 443-2163 so140o@nih.gov
Contact: Mark C Udey, M.D. (301) 496-2481 udey@helix.nih.gov
United States
 
NCT00001506
960102, 96-C-0102
Not Provided
Not Provided
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Mark C Udey, M.D. National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP